Difference between revisions of "Kulkarni 2021 J Med Chem"
(Created page with "{{Publication |title=Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ (2021) A novel triphenylphosphonium carrier to target mitochondria without uncoupling...") Β |
Β |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ (2021) A novel triphenylphosphonium carrier to target mitochondria without uncoupling oxidative phosphorylation. J Med Chem | |title=Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ (2021) A novel triphenylphosphonium carrier to target mitochondria without uncoupling oxidative phosphorylation. J Med Chem 64:662-76. | ||
|info=[https://www.ncbi.nlm.nih.gov/pubmed/33395531 PMID: 33395531] | |info=[https://www.ncbi.nlm.nih.gov/pubmed/33395531 PMID: 33395531] | ||
|authors=Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ | |authors=Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ | ||
|year=2021 | |year=2021 | ||
|journal=J Med Chem | |journal=J Med Chem | ||
|abstract=Mitochondrial dysfunction is an underlying pathology in numerous diseases. Delivery of diagnostic and therapeutic cargo directly into mitochondria is a powerful approach to study and treat these diseases. The triphenylphosphonium (TPP+) moiety is the most widely used mitochondriotropic carrier. However, studies have shown that TPP+ is not inert; TPP+ conjugates uncouple mitochondrial oxidative phosphorylation. To date, all efforts toward addressing this problem have focused on modifying lipophilicity of TPP+-linker-cargo conjugates to alter mitochondrial uptake, albeit with limited success. We show that structural modifications to the TPP+ phenyl rings that decrease electron density on the phosphorus atom can abrogate uncoupling activity as compared to the parent TPP+ moiety and prevent dissipation of mitochondrial membrane potential. These alterations of the TPP+ structure do not negatively affect the delivery of cargo to mitochondria. Results here identify the 4-CF3-phenyl TPP+ moiety as an inert mitochondria-targeting carrier to safely target pharmacophores and probes to mitochondria. | |abstract=Mitochondrial dysfunction is an underlying pathology in numerous diseases. Delivery of diagnostic and therapeutic cargo directly into mitochondria is a powerful approach to study and treat these diseases. The triphenylphosphonium (TPP<sup>+</sup>) moiety is the most widely used mitochondriotropic carrier. However, studies have shown that TPP+ is not inert; TPP<sup>+</sup> conjugates uncouple mitochondrial oxidative phosphorylation. To date, all efforts toward addressing this problem have focused on modifying lipophilicity of TPP<sup>+</sup>-linker-cargo conjugates to alter mitochondrial uptake, albeit with limited success. We show that structural modifications to the TPP<sup>+</sup> phenyl rings that decrease electron density on the phosphorus atom can abrogate uncoupling activity as compared to the parent TPP<sup>+</sup> moiety and prevent dissipation of mitochondrial membrane potential. These alterations of the TPP+ structure do not negatively affect the delivery of cargo to mitochondria. Results here identify the 4-CF3-phenyl TPP<sup>+</sup> moiety as an inert mitochondria-targeting carrier to safely target pharmacophores and probes to mitochondria. | ||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
}} | }} |
Latest revision as of 15:47, 19 October 2021
Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ (2021) A novel triphenylphosphonium carrier to target mitochondria without uncoupling oxidative phosphorylation. J Med Chem 64:662-76. |
Kulkarni CA, Fink BD, Gibbs BE, Chheda PR, Wu M, Sivitz WI, Kerns RJ (2021) J Med Chem
Abstract: Mitochondrial dysfunction is an underlying pathology in numerous diseases. Delivery of diagnostic and therapeutic cargo directly into mitochondria is a powerful approach to study and treat these diseases. The triphenylphosphonium (TPP+) moiety is the most widely used mitochondriotropic carrier. However, studies have shown that TPP+ is not inert; TPP+ conjugates uncouple mitochondrial oxidative phosphorylation. To date, all efforts toward addressing this problem have focused on modifying lipophilicity of TPP+-linker-cargo conjugates to alter mitochondrial uptake, albeit with limited success. We show that structural modifications to the TPP+ phenyl rings that decrease electron density on the phosphorus atom can abrogate uncoupling activity as compared to the parent TPP+ moiety and prevent dissipation of mitochondrial membrane potential. These alterations of the TPP+ structure do not negatively affect the delivery of cargo to mitochondria. Results here identify the 4-CF3-phenyl TPP+ moiety as an inert mitochondria-targeting carrier to safely target pharmacophores and probes to mitochondria.
β’ Bioblast editor: Plangger M
Labels: MiParea: Respiration
HRR: Oxygraph-2k
2021-01